Triple-negative breast cancer 英文论文文献.docVIP

Chacón and Costanzo Breast Cancer Research 2010, 12(Suppl 2):S3 /supplements/12/S2/S3 REVIEW Triple-negative breast cancer Reinaldo D Chacón* and María V Costanzo of metabolic chains and genetic variations (mutation, Abstract deletion or overexpression), all of which gave rise to speci- ? c targets whose optimal use is continually under study. e introduction of HRs in clinical routine use not only showed the usefulness of endocrine therapy in HR- positive cases (60 to 80%) but also the special aggressive- ness of HR-negative cases. Even today, estrogen receptors (ERs) a